["A-triple-V" in refractory or relapsed acute myelocytic leukemia].
Miyawaki
S
S
Nemoto
K
K
Wakamatsu
R
R
Baba
N
N
Yashiro
K
K
Uchida
S
S
Nakura
M
M
Karasawa
M
M
Takada
M
M
Tanaka
H
H
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D014747:Vinblastine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D003561:Cytarabine; D014750:Vincristine; D014747:Vinblastine; D005047:Etoposide; C015019:enocitabine